- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02097706
A Novel Drug for Borderline Personality Disorder
A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder
Borderline Personality Disorder (BPD) is one of the most prevalent psychiatric disorders with high morbidity and mortality. It affects the lives of millions worldwide and is often highly incapacitating, leading to significant psychosocial dysfunction. Moreover, nearly all patients have experienced suicidal ideation and about 10% actually commit suicide, a rate almost 50 times higher than in the general population. Mostly young women are at greater risk for the disorder and are three times more likely to be diagnosed with BPD than men.
BPD aetiology is complex and could be explained by both biological and environmental factors. Among the environmental factors, sexual or physical abuse, parental divorce, loss or illnesses are identified as the most common ones. These factors can induce dysfunctional behaviours, which might cause emotional dysregulation, high impulsivity and frequent self- injurious behaviour.
However, there are no pharmacologic interventions that are known to be specifically effective to treat BPD. Therapeutic options for this devastating disorder is still far from adequate for treating acute illness episodes, relapses, and recurrences and in restoring premorbid functioning. In addition, some patients are unable to tolerate existing therapies for BPD, which leads to either frequent changes in medications or to non-adherence. Therefore there is an urgent need for the development of more rapidly effective treatments for BPD.
A growing body of evidence suggests that glutamatergic neurotransmission, in particular N-methyl-D-aspartate (NMDA) subtype may play a role in the pathophysiology of multiple psychiatric disorders. This has led to various clinical trials with glutamate modulating drugs. The trial drug is an uncompetitive NMDA receptor antagonist approved for Alzheimer's disease is increasingly being studied in a variety of non-dementia psychiatric disorders. Results from these studies have proved that the trial drug was safe and well tolerated and has the potential for use in the treatment of psychiatric disorders.
To date, there are no published data on the use of trial drug in the treatment for BPD. Therefore, the investigators intend to study the efficacy of this novel drug as an addition to ongoing therapy with atypical antipsychotics in patients with Borderline Personality Disorder. This study will recruit 150 BPD patients. The patients will be randomly allocated to receive either the study medication (20mg/ day) or placebo via oral administration for twelve weeks. To observe the efficacy of the trial treatment, all participants will be assessed at various time intervals for different borderline and cognitive symptoms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD
- Phone Number: 66924 +61 3 90766924
- Email: j.kulkarni@alfred.org.au
Study Contact Backup
- Name: Anthony deCastella, DipAppSci,BA,MA
- Phone Number: 66564 +61 3 90766564
- Email: a.decastella@alfred.org.au
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Recruiting
- Monash Alfred Psychiatry Research Centre
-
Contact:
- Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD
- Phone Number: +61 3 9076 6924
- Email: j.kulkarni@alfred.org.au
-
Contact:
- Anthony deCastella, Dip App Sci, BA, MA
- Phone Number: 66554 +61 3 9076 6554
- Email: anthony.decastella@monash.edu
-
Principal Investigator:
- Jayashri Kulkarni AM, MBBS MPM FRANZCP PhD FAHMS
-
Sub-Investigator:
- Anthony deCastella, Dip AppSci,BA,MA
-
Sub-Investigator:
- Caroline Gurvich, PhD
-
Sub-Investigator:
- Eveline Mu, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
Participants will be eligible to proceed in the study if they meet all of the following criteria (as determined in the screening session):
- Men and women aged between 18-65 years of age
- A diagnosis of BPD according to the Diagnostic Interview for Borderline patients or the Zanarini Rating Scale for Borderline Personality Disorder
- Proficient in reading and writing English
Exclusion criteria
Potential participants who meet the criteria for any of the following will be excluded from participating in the study:
- Clinical evidence of CNS pathology, neurological disorder, head injury, epileptic seizures or convulsions.
- Currently pregnant or breastfeeding
- A current DSM-IV-TR diagnosis of substance abuse or dependence disorder, or another Axis I disorder including a past or current diagnosis of schizophrenia, delusional (paranoid) disorder, schizoaffective disorder, bipolar I (mixed, manic, depressed or euthymic) or psychotic depression. Individuals with bipolar II will be included
- Clinically significant and active evidence of liver or kidney disease, hematological, respiratory, endocrine or cardiovascular disease.
- Use of prescription drugs that may cause relevant drug interactions with the study drug according to the summary of product characteristics: NMDAR antagonists (amantadine, ketamine, dextromethorphan), L-Dopa, dopamine agonists and cholinergic agonists.
- Commencing new psychotherapy/ new medication during the trial period.
- History of mental retardation or documented IQ below 75
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NMDA receptor antagonist
20mg/daily for 12 weeks (84 days)
|
|
Placebo Comparator: Placebo tablet
1 capsule/daily for 12 weeks (84 days)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Borderline Evaluation of Severity over Time (BEST)
Time Frame: Weeks 0,2,4,6,8,10,12
|
The Borderline Evaluation of Severity over Time (BEST) is a 15-item self-report measure that allows patients with borderline personality disorder (BPD) to rate the degree of impairment or interference from each of the nine BPD criteria over the past two weeks.
Each time is rated on a 5-point scale, and scores can range from 12 to 72.
Subscales include negative thoughts and feelings, positive behaviours and negative behaviours.
The BEST is used to assess the severity of and change in borderline symptoms over the course of treatment.
|
Weeks 0,2,4,6,8,10,12
|
The Zanarini Rating Scale for Borderline Personality Disorder
Time Frame: Weeks 0, 2, 4, 6, 8, 10, 12
|
The Zanarini Rating Scale is a nine-item, validated, clinician-based diagnostic interview.
It assesses the severity of DSM-IV-based Borderline personality disorder symptoms.
This scale also measures meaningful changes in symptoms over time.
|
Weeks 0, 2, 4, 6, 8, 10, 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cogstate (cognitive assessment)
Time Frame: Baseline and Week 12
|
Cogstate tests have been designed, developed and validated to both identify and measure cognitive impairment, and to track or monitor cognitive change.
The tasks use novel visual and verbal stimuli to ensure assessment is culture-neutral and not limited by a participant's level of education.
|
Baseline and Week 12
|
BPDSI
Time Frame: Baseline and Week 12
|
Borderline Personality Disorder Severity Index-IV (BPDSI-IV)
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD, Bayside Health, Alfred Hospital
Publications and helpful links
General Publications
- Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Grigg J, Tan R, Cheng J, Arnold A, Gurvich C. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial. CNS Drugs. 2018 Feb;32(2):179-187. doi: 10.1007/s40263-018-0506-8.
- Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, Vollm BA, Mattivi JT, Faltinsen E, Todorovac A, Jorgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 204-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Universitat Jaume IHospital de la RiberaNot yet recruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
Rutgers, The State University of New JerseyActive, not recruitingBorderline Personality Disorder in AdolescenceUnited States
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
Clinical Trials on NMDA receptor antagonist (active drug)
-
Federal University of São PauloCompleted
-
PfizerCompletedParkinson's DiseaseUnited States
-
Duke UniversityTerminatedHyperglycemia Drug InducedUnited States
-
PfizerCompletedDepressive Disorder, MajorUnited States
-
New York State Psychiatric InstituteCompletedCocaine Use DisordersUnited States
-
Providence VA Medical CenterMassachusetts Institute of TechnologyUnknownAmputationUnited States
-
University Hospital, CaenUniversity Hospital, Rouen; Central Hospital Saint Quentin; University Hospital... and other collaboratorsUnknown
-
Techfields IncSuspendedIschemic StrokeUnited States
-
Oncolix, Inc.UnknownOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Regor Pharmaceuticals Inc.Recruiting